This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
generally provide “fair access” to 11 treatments for several serious diseases, although transparent coverage information is often lacking for some medicines, a new analysis has found. Most of the formularies run by some of the largest health plans in the U.S. Continue to STAT+ to read the full story…
It is a treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Mounjaro is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. per cent and 2.1
A new government proposal to display nutritional labels on the front of food packaging is aimed at helping Americans make more informed choices about what they eat. An eventual side effect, research and expert commentary suggests, could be nudging the food industry to make healthier food, too.
For someone diagnosed with diabetes, for example, access to nutritious food can be just as important as insulin. But even as new federal incentives require health systems to collect information that would help them identify if that new diabetes patient lives in a food desert, it’s not always clear what to do with that information.
A preliminary evaluation by the Food and Drug Administration did not find evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions.
The Food and Drug Administration is cracking down on websites that claim to sell the underlying chemicals of popular diabetes and obesity drugs like Ozempic, Wegovy, and Zepbound, saying that the websites are selling unapproved and misbranded drug products. DBA Helix Chemical Supply and US Chem Labs.
This information guides the implementation of preventive measures like lifestyle counseling to reduce the risk of ACE-related chronic conditions like depression, obesity, asthma, diabetes, and cancer. It offers physicians a screening tool to evaluate patients, gaining valuable insights into their physical and mental well-being.
While there is no cure for Parkinson’s and treatment options can be daunting, people with the disease can now turn to technology spawned by the Apple Watch to take an active role in their care much as continuous glucose monitors have helped people manage diabetes better. Continue to STAT+ to read the full story…
By the year 2020, he opined, “gene-based designer drugs are likely to be available for conditions like diabetes, Alzheimer’s disease, hypertension, and many other disorders.
Food and Drug Administration rejected Novo Nordisk’s weekly insulin for treating diabetes in a rare setback for the company , STAT tells us. The FTC said its findings were interim, though, because some companies did not provide all of the requested information, and threatened further action. pharmacies in 2023.
UK digital health company Sensyne Health has launched a new smartphone app to help people across the diabetes spectrum manage their condition. The app – called DBm-Health – can help users to monitor their blood glucose levels and send readings, notes and medication information to their healthcare practitioner to assess remotely.
Dr Reddy’s Laboratories announced the launch of its first direct-to-consumer (D2C) e-commerce website ‘Celevida Wellness’ for diabetes patients by its wholly-owned subsidiary, Svaas Wellness. The post Dr Reddy’s launches D2C e-commerce website ‘Celevida Wellness’ for diabetes appeared first on Express Pharma.
November is American Diabetes Month – a time to come together to spread awareness about diabetes prevention and management. In this blog post, we’ll explore key ways pharmacies can actively participate in American Diabetes Month.
Researchers in Germany are have found a possible link between mild COVID-19 infection and an increased risk of type 2 diabetes, although they caution the signal needs further investigation. ” The post Does COVID-19 infection raise the risk of diabetes? .” ” The post Does COVID-19 infection raise the risk of diabetes?
A company statement informed, “InsuQuick is a “Make in India” product, developed and manufactured using 100 per cent indigenous technology, and has undergone a robust clinical program to ensure global quality standards. USV and Biogenomics announced the launch of INSUQUICK, biosimilar Insulin Aspart.
Locked behind the firewalls of proprietary systems sits a treasure trove of data that could help diagnose heart disease, diabetes, cancer, and other conditions faster and more accurately and better treat people with them. Read the rest…
Now, a few tidbits to keep your day informed. Some participants also had type 2 diabetes. ” C’est magnifique! The Phase 3 trial studied patients who had heart failure with preserved ejection fraction (or HFpEF) and obesity.
David Weingard, chief impact officer of T1D Moonshot and founder of Cecelia Health, tells us how T1D Moonshot aims to break silos and advance type 1 diabetes prevention and treatment options by utilising numerous partners’ expertise. million Americans live with diabetes, with 1.6 million having type 1 diabetes (T1D).
The European Medicines Agency backed the use of Novo Nordisk’s Wegovy to lower major heart risks and strokes in overweight or obese adults without diabetes , Reuters notes. Novo plans to add the prescribing information on the Wegovy label in the EU within about one month. regulator, while the U.S. regulator, while the U.S.
insurer is taking an unusually hard line on doctors who it says improperly prescribed the diabetes treatment Ozempic, escalating the ongoing war over drugs that have become wildly popular for weight loss , Bloomberg News reports. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon… A major U.S.
Additionally, she holds the title of Certified Diabetes Care and Education Specialist (CDCES). She says, “With over 80 different languages spoken at my clinic, I worry that information gets lost in translation. Her professional journey demonstrates the versatility inherent in a pharmacy career. About Clinical Pharmacists.
The FTC said its findings were interim, though, because some companies did not provide all of the requested information and threatened further action. billion prescriptions that were dispensed by U.S. pharmacies in 2023.
Clinical-stage biotechnology firm LyGenesis has formed a joint research collaboration with Imagine Pharma to develop new cell therapies for type 1 diabetes (T1D). In June 2022, the company discovered T1D AIPCs, a critical component to treat T1D through autologous cell transplantation.
Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). A Phase I/II study of VCTX211 has been commenced and is currently ongoing. It originated under the partnership of CRISPR Therapeutics and ViaCyte.
The panel committee reviewed non-clinical, clinical, and post-marketing data of the drugs, and said that no updates to their prescribing information was required at the time.
In our latest UK Leaders article Pinder Sahota, UK general manager at Novo Nordisk, tells us how he hopes to bring the NHS and pharma together to improve outcomes in diabetes and other long-term conditions. Collaborating to prevent diabetes. We’ve got two such projects in the UK, in Leicester and Manchester,” says Sahota. “We
Meanwhile, here are a few items of interest to get you started on your own journey, which we hope will be informative and exciting. Right now, Medicare by law cannot cover obesity drugs, though it will pay for seniors to take the same medicines for conditions like diabetes and heart problems. Our choice today is orange creme.
A spokesperson declined to provide further information, citing “privacy issues.” “Our family is deeply saddened about the sudden passing of our beloved Rick but take great comfort knowing he inspired so many,” his family said in the statement released Saturday evening. General said in the statement.
Gabbay, MD, PhD, the ADA’s Chief Science and Medical Officer, American Diabetes Association November is American Diabetes Month® (ADM) at the American Diabetes Association® (ADA). This month often focuses on type 1 and type 2 diabetes. Prediabetes is a condition that comes before diabetes.
A 50-year-old Caucasian female with a history of hypertension, coronary artery disease, and insulin-dependent diabetes mellitus presents to the emergency department with a complaint of painful sores on the top of her left foot. It may be equally common in patients without diabetes, hence was renamed without the term “diabeticorum”.
After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management platform, underpinned by digital technologies. Tighter glucose control is known to reduce the risk of complications of diabetes like cardiovascular disease and nerve damage affecting the eyes and extremities. .
The US Food and Drug Administration has declined to approve Novo Nordisk’s weekly insulin in patients with diabetes, the Danish drugmaker said on Wednesday. The regulator’s decision follows its outside panel’s vote against the use of the weekly insulin icodec, in patients with type 1 diabetes due to risks of low blood sugar.
Francine Kaufman discusses how Senseonics is helping patients monitor their diabetes with the first fully implantable long-term continuous glucose monitoring (CGM) system. Kaufman has been a practicing pediatric endocrinologist with a focus on diabetes for almost 45 years. She joined the team at Senseonics in 2019.
Understanding how patients and healthcare professionals search for medical information is key. Keywords generally fall into three categories: Informational (awareness stage): What are the symptoms of rheumatoid arthritis? best DPP-4 inhibitors for diabetes) keywords balances compliance and visibility. A mix of branded (e.g.,
Earlier this month, the FDA declared an end to the shortage of Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, after almost two years. Food and Drug Administration maintains its list of drug shortages and which sources it relies on, an issue that affects a growing number of Americans , STAT explains.
Union Minister of Chemicals and Fertilizers, and Health and Family Welfare, Jagat Prakash Nadda inaugurated the weeklong celebrations of Jan Aushadhi Diwas, 2025 by flagging off the Rath (Chariot) and 10 other vehicles carrying the information about Pradhan Mantri Bhartiya Janaushadhi Pariyojana from Nirman Bhawan.
The most common pathogen is Klebsiella pneumoniae, and diabetes mellitus is the most common risk factor. Consider it especially in the patient with abdominal pain with diabetes mellitus. Additional Images Physical Exam Vitals : BP 172/71; HR 127; T 35.9°C; mmol/L; Glucose 538 mg/dL CRP : 42.6 mg/dL Ketone body : 5.9 mmHg; pO2 45.8
A company which provides online health testing kits has partnered with Superdrug under a two-year deal to help people ‘make informed decisions about their health and lifestyle’.
The new nano carrier could help people with diabetes avoid side-effects linked to insulin injections such as hypoglycemia, inform the researchers Research led by the University of Sydney and Sydney Local Health District has developed a system using nanotechnology that could allow people with diabetes to take oral insulin in the future.
Genpact, a global professional services and solutions firm delivering outcomes that shape the future, has been working with embecta, a global diabetes care company, to support its spin-off from Becton Dickinson and Company (BD) and subsequent evolution as an independent leader in the diabetes technology market.
According to the Complete Response Letter, the FDA has requested additional information on the manufacturing process and the type 1 diabetes indication for insulin icodec before completing its review.
Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes, heart disease or obesity.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content